Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

BIIB122 225 mg - Phase 2 | DNLI Pipeline | CatalystAlert

BIIB122 225 mg

Phase 2

Denali Therapeutics Inc. (DNLI)

14%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Apr 30

DNLIPhase 2Phase 2

BIIB122 225 mg Phase 2 Results Expected

BIIB122 225 mg • Parkinson Disease

Drug Information

Target Indication

Parkinson Disease

Clinical Trial

Last updated: 12/4/2025

Developer

DNLI

Denali Therapeutics Inc.

Biotechnology•North America•NASDAQ